On August 1, 2012, pSivida Corp. ("pSivida") issued a press release announcing that its partner Alimera Sciences, Inc. intends to resubmit its application for ILUVIEN® for diabetic macular edema to the U.S. Food and Drug Administration using data from its two previously completed pivotal Phase III clinical trials (FAME ™ Study). pSivida's press release is filed as Exhibit 99.1 to this Current Report on Form 8-K.

(d) Exhibits

Exhibit
  No.                                     Description

10.1         pSivida Corp. 2008 Incentive Plan (incorporated by reference to
             Exhibit 10.41 to the Current Report on Form 8-K filed by pSivida on
             June 19, 2008).

99.1         Press Release of pSivida dated August 1, 2012.